Home
Research Principles
Access Issues
Expanded Access
Resources
Lectures
Testimonials
Get Help
Get Involved
Contact

 

  • Consider speaking to your healthcare professional about the maraviroc EAP.
    Maraviroc is an investigational drug being developed for use in combination with other
    antiretroviral medications for the treatment of human immunodeficiency virus, type-1 (HIV-1)
    infected treatment-experienced patients.

    Maraviroceap.com

  • This table summarizes how to apply for two expanded access programs: MK 518-
    Merck's integrase inhibitor and TMC 125- Tibotec's non nucleoside analog. You
    need adobe acrobat reader to open the file ( you can get free adobe reader at)
    http://www.adobe.com/products/acrobat/readstep2.html

    This is the table
    http://aidsinfo.nih.gov/ContentFiles/TB30_AdultandAdolescentGL.pdf

  • EXPANDED ACCESS PROGRAM (EAP) IN THE USA
    Tibotec has opened its expanded access program (EAP) for its investigational
    non-nucleoside reverse transcriptase inhibitor (NNRTI), TMC125, in the U.S. The
    program will provide access for HIV-1 infected patients who need the compound to
    construct a viable treatment regimen.
    Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

  • Enrollment Is Open to Early Access Program for
    Experimental HIV Protease Inhibitor TMC114 with
    Ritonavir in HIV Patients with Limited Treatment
    Options
    This is an open-label safety study to provide early
    access to the promising experimental HIV protease
    inhibitor TMC114 for patients who have failed and
    exhausted regimens based on currently available
    anti-HIV therapy and who are ineligible for
    participation in any other Tibotec-sponsored trial of
    TMC 114. Full article:
    http://www.hivandhepatitis.com/recent/2006/021706_a.html